The Medical Devices and Established Pharmaceuticals segments drive high single-digit growth for Abbott. Check out why ABT ...

Abbott Laboratories has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s ...

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Abbott Laboratories is undervalued by the market, despite its strong fundamentals and strategic moves in high-growth areas like diabetes care and weight-loss treatments. The company boasts a high net ...

Abbott Laboratories (NYSE:ABT) is scheduled to announce its second-quarter earnings on Thursday, July 17, 2025. For traders who focus on events, examining the historical reactions of the stock to ...

Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the August 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is ...

Abbott (NYSE: ABT) recently reported its Q4 results, with revenues marginally below and earnings meeting the street expectations. The company reported revenue of $10.97 billion and earnings of $1.34 ...

$ABT insiders have traded $ABT stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales. We have seen 1,192 ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.